Halofuginone can worsen liver fibrosis in bile duct obstructed rats

Liver International

Volumn 24, Issue 5, 2004, Pages 502-509

  Van de Casteele, Marc ^a   Roskams, Tania ^a   Van der Elst, Ingrid ^a   van Pelt, Jos F ^a   Fevery, Johan ^a   Nevens, Frederik ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Bile ductule; Collagen; Fibrosis; Halofuginone; Rat

Indexed keywords

AMINOPHENAZONE; ANTIFIBROTIC AGENT; CARBON TETRACHLORIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; ENDOTHELIN A RECEPTOR ANTAGONIST; HALOFUGINONE; LOSARTAN; PIOGLITAZONE; RNA; SILYMARIN; MESSENGER RNA; PIPERIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINAZOLINONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT OBSTRUCTION; BILIARY TRACT FIBROSIS; BREATH ANALYSIS; CELL PROLIFERATION; CHOLESTASIS; CONTROLLED STUDY; HEMODYNAMIC MONITORING; LIVER FIBROSIS; LIVER TOXICITY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT; ANIMAL; BILE DUCT; BILIARY CIRRHOSIS; DISEASE MODEL; EXPERIMENTAL LIVER CIRRHOSIS; GENETICS; LIGATION; LIVER; METABOLISM; MORTALITY; OBSTRUCTIVE JAUNDICE; PATHOLOGY; PORTAL VEIN BLOOD PRESSURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WISTAR RAT;

AMINOPYRINE; ANIMALS; BILE DUCTS; BREATH TESTS; CHOLESTASIS, EXTRAHEPATIC; COLLAGEN TYPE I; COLLAGEN TYPE III; DISEASE MODELS, ANIMAL; LIGATION; LIVER; LIVER CIRRHOSIS, BILIARY; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; PIPERIDINES; PORTAL PRESSURE; QUINAZOLINES; QUINAZOLINONES; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 16644377293     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2004.0950.x     Document Type: Article

References (26)

1. Bataller R, Brenner D A. Hepatic stellate cells as a target for the treatment of liver fibrosis. Sem Liver Disease 2001; 21: 437-51.
2. Pines M, Knopov V, Genina O, et al. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J Hepatol 1997; 27: 391-8.
3. Bruck R, Genina O, Aeed H, et al. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 2001; 33: 379-86.
4. Excerpt from the European Veterinary Drug Registry. London, http://www.eudra.org/vetdocs/vets/Epar/halocur/halocur.htm
5. McQuistion T E, McDougald L R. Anticoccidial activity of arprinocid and halofuginone. Vet Parasitol 1981 ;9: 27-33.
6. Granot I, Halevy O, Hurwitz S, et al. Halofuginone: an inhibitor of collagen type I synthesis. Biochim Biophys Acta 1993; 1156: 107-12.
7. Xavier S, Pike E, Fujii M, et al. Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-β signaling by halofuginone. J Biol Chem 2004; 279: 15167-76.
8. Spira G, Mawasi N, Paizi M, et al. Halofuginone, a collagen type I inhibitor improves liver regeneration in cirrhotic rats. J Hepatol 2002; 37: 331-9.
9. Desmet V J. Fibrosis of the liver: a pathologists view. In: Surrenti C, Casini A, Milani S, Pinzani M, eds. Fat-Storing Cells and Liver Fibrosis. Dordrecht: Kluwer Academic Publishers, 1994; 257-73.
10. Roskams T, Desmet V J. Ductular reaction and its diagnostic significance. Semin Diagn Pathol 1998; 15: 259-69.
11. Houry S, Bedossa P, Languille O, et al. Experimental sclerosing cholangitis following intrabiliary injection of formol in the rat. Chirurgie 1992; 118: 693-86.
12. Pappalardo G, Frattaroli F M, Ioppolo A, et al. Secondary sclerosing cholangitis: an experimetal study. Eur Surg Res 1988; 20: 358-63.
13. Grimaud J C, Sastre B, Orsoni P, et al. Role of formalin in the occurrence of sclerosing lesions of the bile ducts. J Chir 1984; 121: 163-9.
14. Zimmermann H, Reichen J, Zimmermann A, et al. Reversibility of secondary biliary fibrosis by bilio-digestive anastomosis in the rat. Gastroenterolcgy 1992; 103: 579-89.
15. Van de Casteele M, Sagesser H, Zimmermann H, Reichen J. Characterisation of portal hypertension models by microspheres in anaesthetised rats: a comparison of liver flow. Pharmacol Ther 2001; 90: 35-43.
16. Irving C S, Schoeller D A, Nakamura K I, et al. The aminopyrine breath test as a measure of liver function. J Lab Clin Med 1982; 100: 356-69.
17. Van de Casteele M, Omasta A, Janssens S, et al. In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats. Gut 2002; 51: 440-5.
18. Puchtler H, Meloan S N, Waldrop F S. Are picro-dye reactions for collagens quantitative? Chemical and histochemical considerations. Histochemistry 1988; 88: 243-56.
19. 4 cirrhotic rat livers might result from low NO synthesis combined with decreased superoxide dismutase activity allowing superoxide-mediated NO breakdown: a comparison of two portal hypertensive rat models with healthy controls. Comp Hepatol 2003; 2: 2.
20. Cho JJ, Hocher B, Herbst H, et al. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology 2000; 118: 1169-78.
21. Boigk G, Stroedter L, Herbst H, et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997; 26: 643-9.
22. Steuber S, Kroker R. Antiprozoika. In: Loescher W, Ungemach FR, Kroker R, eds. Pharmakotherapie bei Haus- und Nutztieren. Berlin: Parey, 1999; 355-77.
23. Yakkundi S, Cannavan A, Elliott C T, et al. Development and validation of a method for the confirmation of halofuginone in chicken liver and eggs using electrospray tandem mass spectrometry. J Chromatogr B 2003; 788: 29-36.
24. Rockey D C. Vasoactive agents in intrahepatic portal hypertension and fibrogenesis: implications for therapy. Gastroenterology 2000; 118: 1261-5.
25. Croquet V, Moal F, Veal N, et al. Hemodynamic and antifibrotic effect of losartan in rats with liver fibrosis and/ or portal hypertension. J Hepatol 2002; 37: 773-80.
26. Tsukamoto H. Hepatic stellate cells as a target for TZD: can we treat liver fibrosis and type II diabetes at the same time? Hepatology 2002; 36: 1011-3.